We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarkers Predict Disease Progression for Patients with Late-stage Brain Tumors

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: A comparison of monocyte and neutrophil phenotype in grade III and grade IV gliomas (Photo courtesy of Jayashree V. Raghavan)
Image: A comparison of monocyte and neutrophil phenotype in grade III and grade IV gliomas (Photo courtesy of Jayashree V. Raghavan)
A team of Indian researchers has identified potential blood-based biomarkers that predict disease progression and survival times for patients with late-stage glioma-type brain tumors.

A glioma tumor starts in the glial cells of the brain or the spine. Gliomas comprise about 30% of all brain tumors and central nervous system tumors, and 80% of all malignant brain tumors. These tumors are heavily infiltrated with immune cells of myeloid origin.

Previous studies have shown that high-grade gliomas have a higher proportion of alternatively activated and suppressive myeloid cells when compared to low-grade gliomas, which correlate with poor prognosis. However, the differences in immune cell phenotypes within high-grade gliomas (between grade III and grade IV or glioblastoma multiforme [GBM]) are relatively less explored, and a correlation of phenotypic characteristics between immune cells in the blood and high-grade tumors has not been performed. Additionally, myeloid cells of granulocytic origin present in gliomas remain poorly characterized.

Investigators at the Indian Institute of Science (Bangalore, India) and their collaborators addressed these questions through phenotypic characterizations of monocytes and neutrophils present in blood and tumors of individuals with glioblastoma or grade III IDH-mutant gliomas.

For this study, the investigators collected blood and tumor samples from patients with grade III and grade IV gliomas, and used a multi-color flow cytometry method to compare the numbers of specific immune monocytes and neutrophils in the samples.

Results revealed that neutrophils comprised a highly heterogeneous population among individuals with glioma, and were different from healthy controls. In addition, CD163 expressing M2 monocytes were present in greater proportions in GBM tissue when compared to grade III IDH-mutant glioma tissue, and a larger proportion of granulocytic myeloid-derived suppressor cells were present in grade III IDH-mutant gliomas when compared to GBM. The expression levels of the surface proteins CD86 and CD63 showed a high correlation between blood and tumor, which suggested that these may be used as possible markers for prognosis.

"Our pilot study suggests that we can potentially use two blood-based biomarkers present on immune cells to identify patients who might not perform well with particular treatment strategies," said senior author Dr. Siddharth Jhunjhunwala, assistant professor of biosystems science and engineering at the Indian Institute of Science. "What our study showed is that you do not need to look at these markers only in the tumors, you might be able to look at these just from the blood, and the clinician can make an assessment."

The study was published in the August 2, 2021, online edition of the journal OncoImmunology.

Related Links:
Indian Institute of Science

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.